Daptomycin Market: Global Industry Analysis and Forecast (2024-2030)

  • Daptomycin Market size was valued at USD 3.81 Bn. in 2023 and the Daptomycin revenue is expected to grow at a CAGR of 3.73% from 2024 to 2030, reaching nearly USD 4.92 Bn. by 2030.

  • Format : PDF | Report ID : SMR_2065

Daptomycin Market Overview:

Daptomycin is the first new natural-product antibiotic launched in a generation. It was licensed first for skin and soft tissue infections (SSTIs) and, more recently, for staphylococcal bacteraemia and endocarditis. Antibiotics are used to treat bacterial infections. They act by either killing germs or preventing microbial growth. Such major and remarkable aspects are notable as a high occurrence of skin and skin structure infections, growing number of patients, increased influence of antibacterial medicine and bacterial metabolite as well as a member of calcium dependent antibiotics, which include emergence into blood stream with sepsis among other things only when they are under some conditions like improved healthcare systems.


Today's growing methicillin-resistant gram-positive bacteria, like MRSA, portend disastrous developments for the development of potent antibiotics like daptomycin. Adoption of daptomycin is aided by heightened patient and healthcare provider awareness of the risks associated with antibiotic resistance and the drug's efficacy. The medicinal uses of daptomycin are increased by ongoing research and development endeavours, clinical studies investigating novel applications, and new combinations. All these factors are propelling the growth of the Daptomycin Market.

Daptomycin Market


To get more Insights: Request Free Sample Report


Daptomycin Market Dynamics:

Antibiotic Resistance and Aging Population are Driving the Growth of Daptomycin Market.

The increasing prevalence of antibiotic resistance, particularly to classical antibiotics, is driving up the demand for daptomycin because it remains resistant to these resistant strains. As endocarditis, bacteraemia and complicated skin and skin structure infections (cSSSI) have become more common, the use of daptomycin across various conditions has broadened its reach into new markets. In view of the susceptibility of older people to infections and their outcomes, serious bacterial infections are increasingly fought with daptomycin. As a result of government programs and funding aimed to prevent resistance to antibiotics and bolster the search for new antibiotics, daptomycin's market is growing.


The market is being propelled forward largely through ongoing clinical trials on Daptomycin's potential uses and through ongoing research that seeks to further elucidate aspects of the drug. The need for efficient antibiotics like daptomycin is increased by the rise of hospital acquired infections (HAIs), which are frequently brought on by organisms that are resistant to several drugs.  Also, use of daptomycin is facilitated by growing awareness among patients and health care providers about its effectiveness in the treatment of infections caused by bacteria that are resistant to treatment with other antibiotics. All these factors are driving the growth of the Daptomycin Market.


High Cost and Potential Adverse Effects Hamper the Growth of the Market.

In comparison to other antibiotics, daptomycin is rather expensive and this limits its use especially where healthcare resources are stretched thin. It is prescribed carefully by healthcare providers because it comes with side effects such as kidney damage or muscle pain even though they are rare in practice. However, the drug loses its potency as time goes by because of bacterial resistance that require development of novel drugs or alternative treatment methods. Newer and emerging antimicrobials face stiff competition because they have better results just like older established anti-infective do, only that they come at an affordable rate or with lesser undesirable effects.  


Strict legal rules exist in the development and introduction of such antibiotics leading to delays before they can reach new formulations or usages. Daptomycin is approved to treat some types of infections. It has less market potential compared to broad-spectrum antibiotics because it is reserved for specific uses. All these factors affect the growth of Daptomycin Market.


Daptomycin Market Segment Analysis:

By Age Group, the Daptomycin Market is divided into Paediatrics and Adults segments. The use of daptomycin in treating adult patients with bacteraemia and right-sided infective endocarditis was the reason for the highest market revenue level in the market. Common diseases like COPD, heart disease, and diabetes raise the risk of infections that need to be treated with powerful antibiotics like daptomycin. Daptomycin is a safer option for elderly people by reducing adverse effects with enhanced supportive care and monitoring methods. Moreover, during the forecast period it is expected that increased adult knowledge on diseases such as ulcerative colitis and periodontitis is anticipated to fuel growth. With all these factors together are driving the growth of the segment in the market.

Daptomycin Market1

Daptomycin Market Regional Insight:

North America, dominates the Daptomycin Market. It is characterised by various factors that influence its growth and adoption of Daptomycin in the region.  One important factor is the frequency of drug-resistant infections, such as vancomycin-resistant enterococci (VRE) and MRSA. Daptomycin is an essential antibiotic in treatment regimens because of its potency against these resistant bacteria. North America has access to state of the art medical treatments and technologies, as well as a highly developed healthcare system. This infrastructure facilitates the broad use of sophisticated antibiotics such as daptomycin.


Prominent research institutes and pharmaceutical businesses that heavily spend in the development of novel antibiotics and formulations are located in the region. Constant research and development works to increase daptomycin's market potential. The government has launched several significant programmes, including financing for R&D, to prevent antibiotic resistance. Antibiotic innovation is supported by initiatives such as CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator). All these factors are fuelling the growth of the Daptomycin Market in the region.

Daptomycin Market2

Daptomycin Market Competitive Landscape:

  • May 2024, Dr. Reddy’s Laboratories launched a generic version of daptomycin for injection in the U.S. market. This product, a 500mg single-dose vial, is a therapeutic equivalent to Cubicin and has been approved by the FDA. This launch is anticipated to increase market competition and improve accessibility for healthcare providers and patients.
  • May 2024, Merck initiated a recall of their Cubicin (daptomycin) product due to contamination with particulate matter identified as glass. This recall highlights the critical importance of stringent quality control measures in pharmaceutical manufacturing to ensure patient safety?(FDA).
  • June 2024, leading pharmaceutical companies, including Teva Pharmaceuticals, Merck, Pfizer, and Cipla, are investing significantly in research and development. These efforts aim to expand their product lines, improve treatment outcomes, and address emerging challenges in antibiotic resistance.


Daptomycin Market Scope:

Daptomycin Market

Market Size in 2023

USD 3.81 Bn.

Market Size in 2030

USD 4.92 Bn.

CAGR (2024-2030)

3.73 %

Historic Data


Base Year


Forecast Period



By Age Group



By Indication

Complicated Skin Structure Infections


By Strength



Regional Scope

North America- United States, Canada, and Mexico

Europe – UK, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe

Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC

Middle East and Africa - South Africa, GCC, Egypt, Rest of the Middle East and Africa

South America – Brazil, Argentina, Rest of South America


Daptomycin Market Key Players:

  1. Teva Pharmaceutical Industries
  2. Merck & Co.
  3. Cipla
  4. Pfizer
  5.  BE Pharmaceuticals
  6. Reddy’s Laboratories
  7. Gland Pharma
  8. Xellia Pharmaceuticals
  9. GlaxoSmithKline Pharmaceuticals
  10. Sun Pharma
  11. Intas Pharmaceuticals
  12. Basic Pharma
  13. Ace Pharmaceuticals
  14. Hikma Pharmaceuticals
  15. Abbott
  16. Ajanta Pharma
  17. Alembic
  18. Alkem
  19. AstraZeneca
  20. Cadila Pharmaceuticals

Frequently Asked Questions

Antibiotic Resistance and Aging Population are the driver of the Daptomycin Market.

1.    Daptomycin Market: Research Methodology 
2.    Daptomycin Market: Executive Summary
3.    Daptomycin Market: Competitive Landscape
4.    Potential Areas for Investment

4.1. Stellar Competition Matrix
4.2. Competitive Landscape
4.3. Key Players Benchmarking
4.4. Market Structure
4.4.1.    Market Leaders 
4.4.2.    Market Followers
4.4.3.    Emerging Players

4.5. Consolidation of the Market
5.    Daptomycin Market Import Export Landscape
5.1. Import Trends
5.2. Export Trends
5.3. Regulatory Compliance
5.4. Major Export Destinations
5.5. Import-Export Disparities
6.    Daptomycin Market: Dynamics
6.1. Market Trends by Region
6.1.1.    North America
6.1.2.    Europe
6.1.3.    Asia Pacific
6.1.4.    Middle East and Africa
6.1.5.    South America

6.2. Market Drivers by Region
6.2.1.    North America
6.2.2.    Europe
6.2.3.    Asia Pacific
6.2.4.    Middle East and Africa
6.2.5.    South America

6.3. Market Restraints
6.4. Market Opportunities
6.5. Market Challenges
6.6. PORTER’s Five Forces Analysis
6.7. PESTLE Analysis
6.8. Strategies for New Entrants to Penetrate the Market
6.9. Regulatory Landscape by Region
6.9.1.    North America
6.9.2.    Europe
6.9.3.    Asia Pacific
6.9.4.    Middle East and Africa
6.9.5.    South America

7.    Daptomycin Market Size and Forecast by Segments (by Value Units)
7.1. Daptomycin Market Size and Forecast, by Age Group (2023-2030)
7.1.1.    Paediatrics
7.1.2.    Adults

7.2. Daptomycin Market Size and Forecast, by Indication (2023-2030)
7.2.1.     Complicated Skin Structure Infections
7.2.2.    Bacteraemia

7.3. Daptomycin Market Size and Forecast, by Strength (2023-2030)
7.3.1.    350mg
7.3.2.    500mg

7.4. Daptomycin Market Size and Forecast, by Region (2023-2030)
7.4.1.    North America
7.4.2.    Europe
7.4.3.    Asia Pacific
7.4.4.    Middle East and Africa
7.4.5.    South America

8.    North America Daptomycin Market Size and Forecast (by Value Units)
8.1. North America Daptomycin Market Size and Forecast, by Age Group (2023-2030)
8.1.1.    Paediatrics
8.1.2.    Adults

8.2. Daptomycin Market Size and Forecast, by Indication (2023-2030)
8.2.1.     Complicated Skin Structure Infections
8.2.2.    Bacteraemia

8.3. Daptomycin Market Size and Forecast, by Strength (2023-2030)
8.3.1.    350mg
8.3.2.    500mg

8.4. North America Daptomycin Market Size and Forecast, by Country (2023-2030)
8.4.1.    United States
8.4.2.    Canada
8.4.3.    Mexico

9.    Europe Daptomycin Market Size and Forecast (by Value Units)
9.1. Europe Daptomycin Market Size and Forecast, by Age Group (2023-2030)
9.1.1.    Paediatrics
9.1.2.    Adults

9.2. Daptomycin Market Size and Forecast, by Indication (2023-2030)
9.2.1.     Complicated Skin Structure Infections
9.2.2.    Bacteraemia

9.3. Daptomycin Market Size and Forecast, by Strength (2023-2030)
9.3.1.    350mg
9.3.2.    500mg

9.4. Europe Daptomycin Market Size and Forecast, by Country (2023-2030)
9.4.1.    UK
9.4.2.    France
9.4.3.    Germany
9.4.4.    Italy
9.4.5.    Spain
9.4.6.    Sweden
9.4.7.    Russia 
9.4.8.    Rest of Europe

10.    Asia Pacific Daptomycin Market Size and Forecast (by Value Units)
10.1. Asia Pacific Daptomycin Market Size and Forecast, by Age Group (2023-2030)
10.1.1.    Paediatrics
10.1.2.    Adults

10.2. Daptomycin Market Size and Forecast, by Indication (2023-2030)
10.2.1.     Complicated Skin Structure Infections
10.2.2.    Bacteraemia

10.3. Daptomycin Market Size and Forecast, by Strength (2023-2030)
10.3.1.    350mg
10.3.2.    500mg

10.4. Asia Pacific Daptomycin Market Size and Forecast, by Country (2023-2030)
10.4.1.    China
10.4.2.    S Korea
10.4.3.    Japan
10.4.4.    India
10.4.5.    Australia
10.4.6.    Indonesia 
10.4.7.    Malaysia
10.4.8.    Vietnam
10.4.9.    Taiwan
10.4.10.    Bangladesh
10.4.11.    Pakistan
10.4.12.    Rest of Asia Pacific

11.    Middle East and Africa Daptomycin Market Size and Forecast (by Value Units)
11.1. Middle East and Africa Daptomycin Market Size and Forecast, by Age Group (2023-2030)
11.1.1.    Paediatrics
11.1.2.    Adults

11.2. Middle East and Africa Market Size and Forecast, by Indication (2023-2030)
11.2.1.     Complicated Skin Structure Infections
11.2.2.    Bacteraemia

11.3. Daptomycin Market Size and Forecast, by Strength (2023-2030)
11.3.1.    350mg
11.3.2.    500mg

11.4. Middle East and Africa Daptomycin Market Size and Forecast, by Country (2023-2030)
11.4.1.    South Africa
11.4.2.    GCC
11.4.3.    Egypt
11.4.4.    Nigeria
11.4.5.    Rest of ME&A

12.    South America Daptomycin Market Size and Forecast (by Value Units)
12.1. South America Daptomycin Market Size and Forecast, by Age Group (2023-2030)
12.1.1.    Paediatrics
12.1.2.    Adults

12.2. South America Market Size and Forecast, by Indication (2023-2030)
12.2.1.     Complicated Skin Structure Infections
12.2.2.    Bacteraemia

12.3. Daptomycin Market Size and Forecast, by Strength (2023-2030)
12.3.1.    350mg
12.3.2.    500mg

12.4. South America Daptomycin Market Size and Forecast, by Country (2023-2030)
12.4.1.    Brazil
12.4.2.    Argentina
12.4.3.    Rest of South America

13.    Company Profile: Key players
13.1. Teva Pharmaceutical Industries    Company Overview    Financial Overview    Business Portfolio    SWOT Analysis    Business Strategy    Recent Developments

13.2. Merck & Co.
13.3. Cipla
13.4. Pfizer
13.5.  BE Pharmaceuticals
13.6. Reddy’s Laboratories 
13.7. Gland Pharma
13.8. Xellia Pharmaceuticals
13.9. GlaxoSmithKline Pharmaceuticals
13.10. Sun Pharma
13.11. Intas Pharmaceuticals
13.12. Basic Pharma
13.13. Ace Pharmaceuticals
13.14. Hikma Pharmaceuticals
13.15. Abbott
13.16. Ajanta Pharma
13.17. Alembic
13.18. Alkem
13.19. AstraZeneca
13.20. Cadila Pharmaceuticals
14.    Key Findings
15.    Industry Recommendation

Enquiry Before Buy

Request Sample PDF